PRIME MEMBER EXCLUSIVE | 3 Months Free Trial
Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.
Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
-
Narrated by:
-
Written by:
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/